

(For reference purpose only – Japanese version prevails in case of any discrepancy)

April 1, 2025

## **Notice Regarding Acquisition of Treasury Shares**

(Acquisition of treasury shares pursuant to the provisions of the Articles of Incorporation pursuant to Article 165-2 of the Companies Act of Japan)

Kaken Pharmaceutical Co., Ltd. (hereinafter referred to as the “Company”) hereby announces that the status of acquisition of treasury shares pursuant to the resolution of the Board of Directors resolved at a meeting held on February 26, 2025 to acquire treasury shares pursuant to Article 156 of the Companies Act of Japan as applied pursuant to Article 165-3 of the Companies Act of Japan.

(1) Class of shares acquired:	Common shares of the Company
(2) Acquisition period:	From March 1, 2025 to March 31, 2025
(3) Total number of shares acquired:	1,050,100 shares
(4) Total amount of acquisition cost:	4,967,507,600 yen
(5) Acquisition method:	Market purchase

### (Reference)

#### I. Details of acquisition of treasury shares

(1) Class of shares to be acquired:	Common shares of the Company
(2) Total number of shares to be acquired:	Up to a maximum of 1.8 million shares (4.52% of the total number of shares issued (excluding treasury shares))
(3) Total amount of acquisition cost:	Up to a maximum of 9,000 million yen
(4) Acquisition period:	From February 27, 2025 to September 30, 2025

#### II. Cumulative total of treasury shares acquired (as of March 31, 2025)

(1) Total number of shares acquired:	1,261,200 shares
(2) Total amount of acquisition cost:	5,933,153,000 yen